Literature DB >> 11761437

Genesis of pituitary adenomas: state of the art.

G Faglia1, A Spada.   

Abstract

In recent years, remarkable progress has been made in the understanding of the pathogenesis of pituitary tumors. Pituitary tumors originate from the uncontrolled proliferation of a single transformed cell in which an initiating event has caused a gain of proliferative function. After the initiation, promoting factors cooperate in the clonal expansion. Common oncogenes, such as ras, are only exceptionally involved. The only activating mutations identified so far are gsp mutations causing the constitutive activation of cAMP pathway. However, gsp-positive adenomas are not associated to a more aggressive tumoral phenotype. The oncogenic potential of gsp mutations is limited by a more rapid degradation of the mutant Gs(alpha) with respect to the wild-type protein, and by a faster removal of cAMP due to increased phosphodiesterase activity. Estrogen-inducible gene sequences with transforming properties (pituitary tumor-transforming gene (PTTG)) have been identified in human pituitary tumors. Human pituitary tumor-transforming gene (hPTTG) is involved both in early pituitary tumorigenesis, as it causes in vitro and in vivo transformation acting as a transcription activator, and in tumor progression, as it regulates the production of basic fibroblast growth factor (bFGF), a potent activator of angiogenesis and mitogenesis. Moreover, a role of cyclin D1 in pituitary tumorigenesis is emerging. The allelic loss of loci for unknown oncosuppressor genes are currently under investigation, while an exceedingly limited role for menin gene and RB1 has been demonstrated for sporadic pituitary tumors. Abnormal methylation that predisposing toward genetic instability may favor the allelic loss or the reduced expression of oncosuppressor genes, is also an emerging field of investigation. Several promoting factors, including the excessive action of physiological stimulators, the defective action of inhibitors, the susceptibility to respond to inappropriate stimuli and the locally produced growth factors, help in tumor progression. The study of homeobox genes that intervene in pituitary cell differentiation may help in expanding our knowledge in pituitary tumor cell genealogy.

Entities:  

Mesh:

Year:  2001        PMID: 11761437     DOI: 10.1023/a:1012988828164

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  128 in total

1.  Frequent loss of the P16INK4a gene product in human pituitary tumors.

Authors:  M Woloschak; A Yu; J Xiao; K D Post
Journal:  Cancer Res       Date:  1996-06-01       Impact factor: 12.701

2.  Structure, expression, and function of human pituitary tumor-transforming gene (PTTG).

Authors:  X Zhang; G A Horwitz; T R Prezant; A Valentini; M Nakashima; M D Bronstein; S Melmed
Journal:  Mol Endocrinol       Date:  1999-01

Review 3.  Genetic basis of endocrine disease: pituitary tumor pathogenesis.

Authors:  I Shimon; S Melmed
Journal:  J Clin Endocrinol Metab       Date:  1997-06       Impact factor: 5.958

4.  An abnormality of thyroid hormone receptor expression may explain abnormal thyrotropin production in thyrotropin-secreting pituitary tumors.

Authors:  N J Gittoes; C J McCabe; J Verhaeg; M C Sheppard; J A Franklyn
Journal:  Thyroid       Date:  1998-01       Impact factor: 6.568

5.  Flow cytometry analysis of pituitary adenomas.

Authors:  O Fornas; M E Mato; M Viader; B Oliver; P Tresserres; F Bartumeus; D Tugues; J Pétriz; X Matías-Guiu; S M Webb
Journal:  Horm Res       Date:  1996

Review 6.  Molecular pathogenesis of pituitary tumors.

Authors:  W E Farrell; R N Clayton
Journal:  Front Neuroendocrinol       Date:  2000-07       Impact factor: 8.606

7.  Analysis of cyclin D1 (CCND1) allelic imbalance and overexpression in sporadic human pituitary tumors.

Authors:  N A Hibberts; D J Simpson; J E Bicknell; J C Broome; P R Hoban; R N Clayton; W E Farrell
Journal:  Clin Cancer Res       Date:  1999-08       Impact factor: 12.531

8.  Oncoprotein immunoreactivity in human pituitary tumours.

Authors:  R Raghavan; D Harrison; P G Ince; R A James; M Daniels; P Birch; G I Caldwell; P Kendall-Taylor
Journal:  Clin Endocrinol (Oxf)       Date:  1994-01       Impact factor: 3.478

9.  Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors.

Authors:  K Nakayama; N Ishida; M Shirane; A Inomata; T Inoue; N Shishido; I Horii; D Y Loh; K Nakayama
Journal:  Cell       Date:  1996-05-31       Impact factor: 41.582

10.  Mutation and cancer: statistical study of retinoblastoma.

Authors:  A G Knudson
Journal:  Proc Natl Acad Sci U S A       Date:  1971-04       Impact factor: 11.205

View more
  16 in total

1.  New roles for pituitary transcription factors.

Authors:  Anna Spada
Journal:  J Endocrinol Invest       Date:  2003-10       Impact factor: 4.256

Review 2.  Paracrinicity: the story of 30 years of cellular pituitary crosstalk.

Authors:  C Denef
Journal:  J Neuroendocrinol       Date:  2008-01       Impact factor: 3.627

Review 3.  Pediatric Pituitary Adenoma: Case Series, Review of the Literature, and a Skull Base Treatment Paradigm.

Authors:  Avital Perry; Christopher Salvatore Graffeo; Christopher Marcellino; Bruce E Pollock; Nicholas M Wetjen; Fredric B Meyer
Journal:  J Neurol Surg B Skull Base       Date:  2018-01-24

4.  Simultaneous symptomatic Rathke's cleft cyst and GH secreting pituitary adenoma: a case report.

Authors:  Lucas J Bader; Kawanaa D Carter; Richard E Latchaw; William G Ellis; Jason A Wexler; Joseph C Watson
Journal:  Pituitary       Date:  2004       Impact factor: 4.107

Review 5.  Cyclic AMP is both a pro-apoptotic and anti-apoptotic second messenger.

Authors:  P A Insel; L Zhang; F Murray; H Yokouchi; A C Zambon
Journal:  Acta Physiol (Oxf)       Date:  2011-05-26       Impact factor: 6.311

6.  Pediatric giant pituitary adenomas: are they different from adults? A clinical analysis of a series of 12 patients.

Authors:  Sumit Sinha; Avijit Sarkari; A K Mahapatra; B S Sharma
Journal:  Childs Nerv Syst       Date:  2014-04-29       Impact factor: 1.475

Review 7.  Mechanisms for pituitary tumorigenesis: the plastic pituitary.

Authors:  Shlomo Melmed
Journal:  J Clin Invest       Date:  2003-12       Impact factor: 14.808

8.  Advances in the Diagnosis, Treatment, and Molecular Genetics of Pituitary Adenomas in Childhood.

Authors:  Margaret F Keil; Constantine A Stratakis
Journal:  US Endocrinol       Date:  2009-02-01

Review 9.  Best Practice No 172: pituitary gland pathology.

Authors:  J W Ironside
Journal:  J Clin Pathol       Date:  2003-08       Impact factor: 3.411

Review 10.  Pituitary tumors in childhood: update of diagnosis, treatment and molecular genetics.

Authors:  Margaret F Keil; Constantine A Stratakis
Journal:  Expert Rev Neurother       Date:  2008-04       Impact factor: 4.618

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.